FibroGen, Yamanouchi Pharmaceuticals Co. Ltd. deal

Yamanouchi licensed Japanese rights to develop and commercialize FibroGen's FG-2216, an oral erythropoietic small molecule in Phase I testing for anemia. FG-2216 stabilizes hypoxia inducible factor (...